Serum vascular endothelial growth factor in Iranian patients with moderate-severe psoriasis before and after treatment: a PASI-75 response as a practical treatment goal
Authors
Abstract:
Background: Psoriasis is a chronic disease with multiple biochemical and vascular abnormalities. Several studies have evaluated circulating levels of vascular endothelial growth factor (VEGF) in psoriasis, but none of them evaluated it after reaching a PASI-75 response, as a practical treatment goal. The aim of this study was to evaluate serum levels of VEGF in moderate to severe psoriatic patients before and after treatment compared with healthy controls.Methods: This study was approved by the Ethics Committee of Shahid Beheshti University of Medical Sciences. Fifty-eight patients with moderate- severe psoriasis and 60 age-and gender-matched healthy controls were recruited to this study. Serum VEGF levels (pg/ml) of both groups were measured. We used Psoriasis Area and Severity Index (PASI) scoring to assess disease activity in patients. According to the disease severity, the patients received proper treatment. When they reached a PASI-75 response, serum VEGF levels were measured once more.Results: In our study, the median serum VEGF level was significantly higher in psoriatic patients (before and after treatment) as compared to healthy controls. Moreover, patients showed a significant reduction in their serum VEGF levels after reaching PASI-75. The median time of therapeutic effect (reaching a PASI- 75 response) was four months. Furthermore, our study showed a significant correlation between the serum VEGF level and age, BMI, PASI, and disease duration (P
similar resources
Molecular Study of Vascular Endothelial Growth Factor Gene in Iranian Patients after Myocardial Infarction
Background: Stimulation of collateral artery growth (arteriogenesis) and/or capillary network growth (angiogenesis) would be beneficial to the patients with myocardial infarction. To understand the central role of vascular endothelial growth factor (VEGF) in biological angiogenesis, we performed molecular analysis of the VEGF gene in patients afflicted with acute myocardial infarction (AMI). Me...
full textAlterations in plasma vascular endothelial growth factor levels in patients with schizophrenia before and after treatment.
Vascular endothelial growth factor (VEGF), a potent angiogenetic factor, is a known neurotrophic factor. In this study, we examined plasma levels of VEGF in 50 patients with schizophrenia (SPR) and 50 healthy control subjects. We also explored any changes in plasma VEGF levels after 6-week treatment with antipsychotic agents in patients with schizophrenia. All subjects with schizophrenia were e...
full textDiagnostic Value of Serum Levels of Vascular Endothelial Growth Factor as a Marker of Tubal Pregnancy
Background and purpose: Tubal pregnancy is a life threatening condition that not only causes mortality but also reduces fertility by less than 50%. In many patients, the level of βhCG does not reach detection threshold, and for definite diagnosis, long-term follow-up considering βhCG titration and transvaginal ultrasonography are needed which could lead to delay in diagnosis and treatment. The ...
full textSerum and Peritoneal Fluid Levels of Vascular Endothelial Growth Factor in Women with Endometriosis
full text
Vascular Endothelial Growth Factor Level in Patients With Oral Lichen Planus: A Systematic Review and Meta-Analysis Study
Background: According to the possible role of Vascular Endothelial Growth Factor (VEGF) in the incidence of oral lichen planus lesions, it seems necessary to evaluate it in patients with Oral Lichen Planus (OLP). Objective: The present study aims to investigate the level of VEGF in patients with OLP. Methods: In this systematic review and meta-analysis study, the search was conducted in online...
full textMy Resources
Journal title
volume 19 issue 4
pages 119- 124
publication date 2016-10-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023